- Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer immunotherapy and translational cancer immunology - LIfT BioSciences’ lead IMAN-based drug candidate is a groundbreaking next-generation immunotherapy designed to treat patients with treatment-resistant cancers London, May 07, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the formation of its Sci

- Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease context - LIfT BioSciences’ immuno-modulatory alpha neutrophils (IMANs) are designed to have the potent anti-tumour activity of naturally occurring N1 neutrophils fixed into their biology London, April 22, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the publica

- Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named Interim CEO - Alex Blyth, Founder and CEO to step down and will continue to work with the Company at a Board level - LIfT BioSciences is currently advancing its first IMAN-based product and preparing to initiate a first-in-human Phase 1 clinical trial. This groundbreaking next-generation immunotherapy aims to target patients with treatment-resistant cancers. London, January 7, 2026 – LIfT BioS